Identified protein signatures defining the five main types of breast cancer.
Established serum biomarker signatures that allow risk classification of tumor recurrence in breast cancer.
Discovered new genomic breast cancer subtypes on whole-genome patterns of DNA aberrations.
Identified specific DNA methylation patterns in different subtypes of breast cancer.
Discovered a prognostic gene expression signature from sub-classification of HER2 expressing breast cancers.
Developed microarray-based serum biomarker signatures that identify stage I/II pancreatic cancer, forming the basis for a commercially available diagnostic test.
Designed a novel serum-based clinical test for ovarian cancer, which makes it possible to distinguish benign, malignant and 'borderline' cases.
Discovered gene expression subtypes with correlation to prognosis in stage IV malignant melanoma.
Cancer treatment and therapeutic targets
Discovered an association between the expression of the erythropoietin (EPO) receptor and Tamoxifen response in breast cancer, lymphoma, and ovarian cancer patients.
Identified HIF-2a as a therapeutic target of tumor stem cells of neurally derived tumors.
SOX11 as a potential tumor suppressor gene in mantle cell lymphoma and ovarian cancer, as well as an improved histological biomarker for classifying lymphomas.
Developed a novel proteomic technology platform entitled Global Proteome Survey (GPS), capable of transforming affinity proteomics to a global discovery engine. The GPS combines the best features of affinity proteomics with mass-spectrometry and is based on antibodies specific for short peptide motifs shared by many proteins – CIMS antibodies.
Developed a high-throughput and sensitive protein affinity extraction platform, which directly interfaces with MALDI. This offers new means for rapid screening of biomarkers in complex biofluids – AFFIRM.
Affinity Proteomics - Developed a robust, multiplexed antibody microarray platform where hundreds of serum protein can be screened. The general conclusions from analyzing several different complex disease indications, is that 10-20 serum proteins can be combined into a biomarker “signature” with the power to discriminate different complex disease indications.
Developed methods to monitor the state of DNA repair pathways, which opens up for defining targets for therapeutic interventions.